The journey from a Letter of Intent to a final agreement is often perilous, with the parties’ discussions and intentions wrangled by lawyers and company executives to memorialize deals with merger clauses. In Apex Health, Inc. v. Atrium Health, Inc., 2026 NCBC 10, plaintiff Apex learned from the Business Court that failing to adequately tether the agreement to what was set forth in an LOI was a potential $62 million problem.

The dispute centered around Medicare Advantage plans which private insurers like Apex can offer as alternatives to traditional Medicare. In these MA plans, the offering private insurer is paid a static monthly reimbursement for each beneficiary that it enrolls. Atrium decided to offer its own MA plan but began discussions with Apex under which the insurer would bear the venture’s financial risks. Atrium envisioned a “narrow network” that offered care only from Atrium providers, but the format carried greater risk for Apex because potential enrollees would likely face more limited treater options as compared to traditionally empaneled networks. Id. ¶¶ 11, 14-16.

The crux of the dispute was whether Atrium actually agreed to the type of collaborative, co-branded support for the MA plan that Apex believed was necessary to overcome the risks of offering a product focused solely on Atrium’s providers. It was a high-stakes question, as Apex alleged Atrium’s lack of support for the MA plan resulted in fewer than 50 enrollees in 2021, 150 in 2022, and an approximately $62 million loss when the plan failed. Id. ¶¶ 38, 42-43.

The Court observed that the parties did discuss the importance of Atrium’s fulsome support for the potential MA plan as they evaluated, and ultimately signed, an LOI. Apex Health alleged it made clear to Atrium that its “complete buy in and support as a true partner” would be required, and that in its communications Atrium referred to it as “our own MA Product.” Id. ¶¶ 18-19.

In an email to Apex before the LOI was signed, an Atrium representative indicated an internal recommendation had been made “to move forward with Apex Health as our selected partner to deliver a co-branded Medicare Advantage Plan.” The parties’ LOI stated they intended to enter an “arrangement to form a co-branded, high-performing network Medicare Advantage health plan.” Id. ¶¶ 20-21.

The problem, Judge Earp observed, is that the parties’ agreement to develop an MA plan didn’t carry forward the one-for-all spirit Apex alleges it depended on. Instead, the agreement simply indicated the parties’ “desire to collaborate on the Plan as set forth in this Agreement,” and that Atrium committed to “use commercially reasonable efforts to support [Apex’s] marketing efforts[.]” Id. ¶¶ 26-28. The Court noted the agreement did not contain a co-branding commitment, refer to the MA as Atrium’s “own,” or “include any specifics regarding how the Plan would be marketed.” Id. ¶ 67. As the Court noted (¶ 69):

“If Apex thought the marketing arrangement to be of paramount importance . . . one wonders why it was left to chance.

. . .

“Given its sophistication and experience in the industry, Apex could have done more to set out its expectations regarding ‘co-branding’ and ‘partnership’ in the Agreement.”

Against this background, the Court was unmoved by Apex’s motion to amend its complaint to add a Chapter 75 claim. It found Apex’s allegations of a “pattern of deception” fell short of the “egregious and aggravating circumstances” standard required where a contract underlies the dispute. Id. ¶¶ 63, 70. The Court observed that discovery had, at best, shown that Atrium’s executives didn’t agree internally on the extent to which the company would support the MA plan in the manner Apex believed the LOI envisioned.

Undue Delay in Seeking Amendment

Apex sought leave to amend about two months prior to a discovery close that had been extended three times at the parties’ request. Coupled with the motion coming “months after discovery revealed the documents” on which Apex relied to show deception in Atrium’s approach to negotiating the MA agreement, the Court noted that “both sides have back-end loaded their discovery efforts.” The Court noted that no contemporaneous concerns about the pace of document productions or deposition scheduling delays had been raised: “They managed the (extended) discovery period in this manner at their own peril.” Id. ¶¶ 46-48, 78.

Worth Noting

•  Apex contended that it was not seeking to amend for a fraud claim, but the Court found its allegations that “Atrium deceived Apex into agreeing to the terms of the Agreement without ever intending to give the Plan preferential marketing treatment” were “allegations sounding in fraudulent inducement” that had to be pled with particularity under N.C. R. Civ. P. 9(b). Id. ¶¶ 71-72.

Brad Risinger is a partner in the Raleigh office of Fox Rothschild LLP.